Pay in 4 interest-free payments of $5.75 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
In exploring the treatment of obesity and its associated complications, such as Type 2 diabetes and cardiovascular disease, a prominent and popular target is the Glucagon-Like Peptide-1 Receptor (GLP-1R)
:
Some GLP-1 medications, like tirzepatide, also act on GIP (glucose-dependent insulinotropic polypeptide) receptors, which is why tirzepatide is sometimes called a "dual agonist." Mechanism of action (based on published research): According to research published in peer-reviewed journals, GLP-1 receptor agonists work through several mechanisms: They slow gastric emptying, which can increase feelings of fullness after meals
For patients who fall into this category, their prescribing physician now has stronger clinical grounds to recommend or continue Ozempic as part of a broader treatment plan that addresses cardiovascular risk alongside glycemic control
Thus, individualized regimens should be anticipated for groups with different metabolic profiles and clinical stages
